Skip to main content
Log in

Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

A previous study showed that most ankylosing spondylitis (AS) patients presented recurrence within 6 months post-discontinuation of etanercept. How to reduce recurrence following discontinuation of etanercept should be further researched. In this study, 111 ankylosing spondylitis patients meeting the Assessment in AS 20 % response (ASAS20) criteria after 12-week administration of etanercept were randomized into three groups: Group I, 150 mg thalidomide once/day; Group II, 1 g sulfasalazine, twice/day; Group III, NSAIDs for the maintenance treatment. The patients were regularly followed up once a month, and AS recurrence was evaluated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the patient global assessment (PGA), and rachialgia. The follow-up lasted for 1 year, and AS recurrence was considered as the end of a visit. Finally, 100 patients completed the follow-up study, of whom 30 were in Group I, 33 in Group II, and 37 in Group III. The average follow-up period was 5.1 ± 3.9 months and the longest lasted for 12 months. At the end of the follow-up study, the recurrence rates in Groups I, II, and III were, respectively, 60.0 % (18/30), 84.8 % (28/33), and 89.2 % (33/37). The recurrence rates of Group I were statistically significantly lower than that of Group II and III (P = 0.0265; P = 0.0053), while there was no significant difference between Group II and Group III. In addition, we found that PGA, C-reactive protein (CRP), and spinal inflammation could be regarded as predictive factors for AS recurrence by analysis with the Cox proportional hazard model. This study points to a new way for maintenance therapy of AS following discontinuation of etanercept and reveals several useful indicators for prediction of AS recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Silva EM, Andrade SC, Vilar MJ (2011) Evaluation of the effects of Global Postural Reeducation in patients with ankylosing spondylitis. Rheumatol Int 32:2155–2163

    Article  PubMed  Google Scholar 

  2. Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613

    CAS  PubMed  Google Scholar 

  3. Goh L, Samanta A (2009) A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29:1123–1135

    Article  CAS  PubMed  Google Scholar 

  4. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675

    Article  CAS  PubMed  Google Scholar 

  5. Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, Triolo G (2010) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30:1437–1440

    Article  PubMed  Google Scholar 

  6. Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342–348

    Article  CAS  PubMed  Google Scholar 

  7. Moghimi J, Sheikhvatan M, Semnani V (2011) The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int 32:2271–2274

    Article  PubMed  Google Scholar 

  8. Lian F, Yang X, Liang L, Xu H, Zhan Z, Qiu Q, Ye Y (2011) Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 32:1663–1667

    Article  PubMed  Google Scholar 

  9. Ferraz MB, Tugwell P, Goldsmith C, Atra E (1990) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17:1482

    CAS  PubMed  Google Scholar 

  10. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR Jr, Taylor T, Budiman-Mak E (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2004–2012

    Article  CAS  PubMed  Google Scholar 

  11. Huang F, Wei J, Breban M (2002) Thalidomide in ankylosing spondylitis. Clinical and experimental rheumatology 20:158–161

  12. Wei JCC, Chan TW, Lin HS, Huang F, Chou CT (2003) Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 30:2627–2631

    CAS  PubMed  Google Scholar 

  13. Davis JC, Huang F, Maksymowych W (2003) New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheum Dis Clin North Am 29:481–494

    Article  PubMed  Google Scholar 

  14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286

    CAS  PubMed  Google Scholar 

  15. Stone MA, Inman RD, Wright JG, Maetzel A (2004) Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Care Res (Hoboken) 51:316–320

    Article  CAS  Google Scholar 

  16. Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Care Res (Hoboken) 53:856–863

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jianglin Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deng, X., Zhang, J., Zhang, J. et al. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int 33, 1409–1413 (2013). https://doi.org/10.1007/s00296-012-2571-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2571-5

Keywords

Navigation